

Election of Species

In accordance with MPEP 803.02 Applicants hereby provisionally elect the species identified by Example 154: 2-[5-[3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-[1,3,4]oxadiazol-2-ylamino]-propane-1,3-diol for the purposes of examination only.

Applicants believe that Claims 1 and 2 read on this elected species.


Conclusion

Applicants believe all claims are now in condition for allowance. Should there be any issues that have not been addressed to the Examiner's satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

Applicants do not believe any fees are due in connection with this response. If any fees are due in connection with this response, please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: November 4, 2005


Galina M. Yakovleva, Ph.D.
Attorney For Applicants
Registration No. 47,192

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-6095
Fax: (858) 678-8233